 |
 |
| November 21, 2011 |
Proteonomix, Inc. |
 |
Proteonomix, Inc. (PROT) Announces Material Agreement With the University of Miami to Conduct a Clinical Study of UMK 121 in Patients With End Stage Liver Disease. |
 |
MOUNTAINSIDE, NJ--(Marketwire -11/21/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has entered into an agreement with the University of Miami ("The University") to conduct a Clinical Study entitled "UMK 121 in Patients with Liver Disease." |
|
| Read Full Story > |
 |
 |
| November 11, 2011 |
Proteoderm, Inc. |
|
Subsidiary Proteoderm, Inc. Has Received the Approval of Its Application for INCI Registration of Its Matrix NC-138 by the Cosmetic Ingredient Review Panel and Is Now Able to Commercialize Its Product in the USA. |
|
MOUNTAINSIDE, NJ--(Marketwire -11/11/11)- PROTEONOMIX, INC. (OTC.BB: PROT.OB - News), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the Cosmetic Ingredients Review Board ("CIR") has approved and assigned an INCI nomenclature to its innovative Matrix NC-138 Cosmeceutical product, a necessary final step prior to manufacturing and commercialization of cosmetic products in the United States. |
|
| Read Full Story > |
|
